Richard Ward is a Director in the Oncology Search and Evaluation Group in AstraZeneca. Richard recently moved into business development after working as a Computational Medicinal Chemist in drug discovery projects within Oncology R&D at AstraZeneca for almost 20 years. Richard was co-proposer and co-inventor of the approved EGFR mutant-selective covalent inhibitor osimertinib (Tagrisso) and co-inventor of the ERK1/2 inhibitor AZD0364. As part of this discovery work he was recently awarded the Heroes of Chemistry award by the ACS, the Malcolm Campbell Memorial Prize by the RSC and has also been the awarded the 8th Capps Green Zomaya Award by the Biological and Medical Chemistry sector of the RSC. Before starting his research career at AstraZeneca, Richard was gained a BSc in Chemistry and Bio-organic Chemistry and a PhD in Computational Chemistry at The University of Birmingham, UK.
9:00 AM - 9:55 AM
Thursday, June 11
The Federal Lab Consortium (FLC) is a nationwide network representing a non-dilutive, comprehensive…